Downregulation of filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer

Molecular Cancer Research

Volumn 9, Issue 8, 2011, Pages 1126-1138

  Burton, Elizabeth R ^a   Gaffar, Aneesa ^a   Lee, Soo Jin ^a   Adeshuko, Folashade ^a   Whitney, Kathleen D ^a   Chung, Joon Yong ^b   Hewitt, Stephen M ^b   Huang, Gloria S ^a   Goldberg, Gary L ^a   Libutti, Steven K ^a   Kwon, Mijung ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FILAMIN A INTERACTING PROTEIN 1 LIKE; MESSENGER RNA; TUMOR PROMOTER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL INVASION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CPG ISLANDS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYTOSKELETAL PROTEINS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHENOTYPE; PROMOTER REGIONS, GENETIC;

EID: 80051957383     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0162     Document Type: Article

References (40)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
2. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-181
3. Mazzanti C.M., Tandle A., Lorang D., Costouros N., Roberts D., Bevilacqua G., et al. Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res 2004;14:1585-1593 (Pubitemid 39193409)
4. Tandle A.T., Mazzanti C., Alexander H.R., Roberts D.D., Libutti S.K. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine 2005;30:347-358 (Pubitemid 40780967)
5. Kwon M., Hanna E., Lorang D., He M., Quick J.S., Adem A., et al. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res 2008;68:7332-7341
6. Mok S.C., Wong K.K., Chan R.K., Lau C.C., Tsao S.W., Knapp R.C., et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994;52:247-252 (Pubitemid 24064379)
7. Matei D., Graeber T.G., Baldwin R.L., Karlan B.Y., Rao J., Chang D.D. Gene expression in epithelial ovarian carcinoma. Oncogene 2002;21:6289-6298
8. Quaye L., Dafou D., Ramus S.J., Song H., Gentry-Maharaj A., Notaridou M., et al. Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet 2009;18:1869-1878
9. Notaridou M., Quaye L., Dafou D., Jones C., Song H., Hogdall E., et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer 2011;128:2063-2074
10. Barton C.A., Hacker N.F., Clark S.J., O'Brien P.M. DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109:129-139
11. Matei D.E., Nephew K.P. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol 2010;116:195-201.
12. Shepherd T.G., Theriault B.L., Campbell E.J., Nachtigal M.W. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 2006;1:2643-2649
13. Ehrich M., Turner J., Gibbs P., Lipton L., Giovanneti M., Cantor C., et al. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci 2008;105:4844-4849 (Pubitemid 351753834)
14. Radpour R., Haghighi M.M., Fan A.X., Torbati P.M., Hahn S., Holzgreve W., et al. High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Mol Cancer Res 2008;6:1702-1709
15. Radpour R., Kohler C., Haghighi M.M., Fan A.X., Holzgreve W., Zhong X.Y. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 2009;20;28:2969-2978
16. Vanaja D.K., Ehrich M., Van den Boom D., Cheville J.C., Karnes R.J., Tindall D.J., et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest 2009;27:549-560
17. DiSaia P.J., Creasman W.T. Clinical gynecologic oncology. 6th ed. St. Louis, MO: Mosby; 2002.
18. Mayr B., Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609. (Pubitemid 33674011)
19. Mancini D.N., Rodenhiser D.I., Ainsworth P.J., O'Malley F.P., Singh S.M., Xing W., et al. CpG methylation within the 50 regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 1998;16:1161-1169 (Pubitemid 28127515)
20. DiNardo D.N., Butcher D.T., Robinson D.P., Archer T.K., Rodenhiser D.I. Functional analysis of CpG methylation in the BRCA1 promoter region. Oncogene 2001;20:5331-5340 (Pubitemid 32844064)
21. Yossifoff M., Kisliouk T., Meiri N. Dynamic changes in DNA methylation during thermal control establishment affect CREB binding to the brain-derived neurotrophic factor promoter. Eur J Neurosci 2008;28:2267-2277
22. Fox K.E., Colton L.A., Erickson P.F., Friedman J.E., Cha H.C., Keller P., et al. Regulation of cyclin D1 and Wnt10b gene expression by cAMPresponsive element-binding protein during early adipogenesis involves differential promoter methylation. J Biol Chem 2008;283:35096-35105
23. Kuroda A., Rauch T.A., Todorov I., Ku H.T., Al-Abdullah I.H., Kandeel F., et al. Insulin gene expression is regulated by DNA methylation. PLoS one 2009;4:e6953.
24. Sunahori K., Juang Y.T., Tsokos GC. Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase Ac alpha promoter determines CREB binding and activity. J Immunol 2009;182:1500-1508
25. Kim H.P., Leonard W.J. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: A role for DNA methylation. J Exp Med 2007;204:1543-1551 (Pubitemid 47048022)
26. He A., Pu WT. Genome-wide location analysis by pull down of in vivo biotinylated transcription factors. Current protocols in molecular biology Wiley; 2010.
27. Wiley A., Katsaros D., Chen H., Rigault de la Longrais I.A., Beeghly A., Puopolo M., et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006;107:299-308. (Pubitemid 44036559)
28. Wang C., Horiuchi A., Imai T., Ohira S., Itoh K., Nikaido T., et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004;202:215-223 (Pubitemid 38208659)
29. Rathi A., Virmani A.K., Schorge J.O., Elias K.J., Maruyama R., Minna J.D., et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002;8:3324-3331 (Pubitemid 35340705)
30. Makarla P.B., Saboorian M.H., Ashfaq R., Toyooka K.O., Toyooka S., Minna J.D., et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005;11:5365-5369 (Pubitemid 41060809)
31. Kang S., Dong S.M., Park N.H. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer. Gynecol Oncol 2010;118:58-63.
32. Morgan R.J. Jr. Ovarian cancer guidelines: Treatment progress and controversies. J Natl Compr Canc Netw 2011;9:4-5.
33. Asadollahi R., Hyde C.A., Zhong X.Y. Epigenetics of ovarian cancer: From the lab to the clinic. Gynecol Oncol 2010;118:81-87
34. Balch C., Huang T.H., Brown R., Nephew K.P. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004;191:1552-1572 (Pubitemid 39491180)
35. Fu S., Hu W., Iyer R., Kavanagh J.J., Coleman R.L., Levenback C.F., et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer Epub2010 Nov 8.
36. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine- induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-6044
37. Schwarze S.R., DePrimo S.E., Grabert L.M., Fu V.X., Brooks J.D., Jarrard D.F. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 2002;277:14877-14883 (Pubitemid 34952561)
38. Schwarze S.R., Fu V.X., Desotelle J.A., Kenowski M.L., Jarrard D.F. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 2005;7:816-823
39. Poole L.J., Yu Y., Kim P.S., Zheng Q.Z., Pevsner J., Hayward G.S. Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol 2002;76:3395-3420 (Pubitemid 34224543)
40. Klener P., Szynal M., Cleuter Y., Merimi M., Duvillier H., Lallemand F., et al. Insights into gene expression changes impacting B-cell transformation: Cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. J Virol 2006;80:1922-1938 (Pubitemid 43228732)